Company: GNMSF
Filing Date: 2025-08-07
Form Type: 6-K
Source: 0001434265-25-000063
Chunk: 42

Company: GENMAB A/S
Filing Date: 2025-08-07
Form: 6-K
Chunk 42
---
 Acquisition and integration related charges in Genmab’s Condensed Consolidated Statements of Comprehensive Income related to professional due diligence procedures in connection with the acquisition of ProfoundBio. The $ 16million of Acquisition and integration related charges incurred prior to the Acquisition Date and the $ 20million of Acquisition and integration charges incurred from the Acquisition Date through June 30, 2024 total $ 36million.

| Genmab A/S            
 Carl Jacobsens Vej 30 
 2500 Valby, Denmark   |     | Tel: +45 7020 2728 
 www.genmab.com     |     | Company Announcement no. 40 
 Page 34/44                  
 CVR no. 2102 3884           |

#### Interim Report for the First Half of 2025
The following table provides Genmab’s consolidated revenue and net profit for the first six months of 2024 as if the acquisition of ProfoundBio had occurred on January 1, 2024:

|            |     | Six Month Period Ended June 30, 2024 |       |
|:-----------|:----|:-------------------------------------|------:|
| Revenue    |     |                                      | 1,382 |
| Net Profit |     |                                      |   364 |

The unaudited pro forma information does not necessarily reflect the actual results of operations of the combined entities that would have been achieved, nor are they necessarily indicative of future results of operations. The unaudited pro forma information reflects certain adjustments that were directly attributable to the acquisition of ProfoundBio, including additional amortization adjustments for the fair value of the technology platform intangible asset acquired.

As of June 30, 2024, Cash and cash equivalents in Genmab’s Condensed Consolidated Balance Sheets includes $ 30million of restricted cash balances for funds held in escrow related to the acquisition of ProfoundBio.

Note 3 - Revenue

The table below summarizes Genmab’s revenue by type and collaboration partner, and royalties by product, under Genmab’s agreements.

| Revenue by type:                  |     | Three Months Ended June 30, 
 2025                        |     |     | 2024 |     |     | Six Months Ended June 30, 
 2025                      |       |     | 2024 |       |
|:----------------------------------|:----|:----------------------------|----:|:----|:-----|----:|:----|:--------------------------|------: